Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 32.50 GBp
Change Today +0.50 / 1.56%
Volume 116.0K
SNG On Other Exchanges
Symbol
Exchange
London
As of 11:30 AM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

synairgen plc (SNG) Snapshot

Open
32.00 GBp
Previous Close
32.00 GBp
Day High
32.50 GBp
Day Low
32.00 GBp
52 Week High
06/12/14 - 86.00 GBp
52 Week Low
02/16/15 - 26.50 GBp
Market Cap
29.7M
Average Volume 10 Days
112.6K
EPS TTM
0.02 GBp
Shares Outstanding
91.3M
EX-Date
--
P/E TM
18.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for SYNAIRGEN PLC (SNG)

Related News

No related news articles were found.

synairgen plc (SNG) Related Businessweek News

No Related Businessweek News Found

synairgen plc (SNG) Details

Synairgen plc discovers and develops respiratory drugs with a focus on viral defense of the lungs in the United Kingdom. It develops inhaled interferon beta (IFN-ß) programmes comprising IFN-ß in Asthma, a programme to reduce cold virus-induced asthma exacerbations, which is in Phase II clinical trials; IFN-ß in COPD, a programme for the treatment of rhinovirus-induced chronic obstructive pulmonary disease exacerbations that has completed Phase I clinical trials; and IFN-ß in severe viral lung infection, a programme for the treatment of various viral lung infections. The interferon beta is a natural protein found in the body that helps to regulate the immune system and fight off viruses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Founded in 2004

synairgen plc (SNG) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: 130.0K GBP
Finance Director, Company Secretary and Execu...
Total Annual Compensation: 118.0K GBP
Chief Scientific Officer and Executive Direct...
Total Annual Compensation: 97.0K GBP
Compensation as of Fiscal Year 2013.

synairgen plc (SNG) Key Developments

Synairgen Reports Unaudited Consolidated Earnings Results for the Full Year Ended December 31, 2014

Synairgen reported unaudited consolidated earnings results for the full year ended December 31, 2014. For the year, revenue was £4,290,000. Profit from operations was £1,094,000 against loss from operations of £2,278,000 a year ago. Profit before tax was £1,125,000 against loss before tax of £2,267,000 a year ago. Profit and total comprehensive income for the period attributable to equity holders of the parent was £1,188,000 against loss and total comprehensive loss for the period attributable to equity holders of the parent of £2,043,000 a year ago, driven by initial receipt from AstraZeneca of £7.25 million received in June 2014. Diluted earnings per share were 1.35 pence against 2.72 pence a year ago. Net cash generated from operating activities was £1,803,000 against net cash used in operating activities of £1,791,000 a year ago. Purchase of property, plant and equipment was £14,000 against £3,000 a year ago. Purchase of intangible assets was £4,000 against £16,000 a year ago.

Synairgen, 2014 Earnings Call, Mar 03, 2015

Synairgen, 2014 Earnings Call, Mar 03, 2015

Synairgen Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2014

Synairgen announced unaudited consolidated earnings results for the six months ended June 30, 2014. For the six months, the company announced revenue of GBP 4,250,000. Profit from operations was GBP 1,886,000 compared to loss from operations of GBP 1,202,000 for the same period a year ago. Profit before tax was GBP 1,890,000 compared to loss before tax of GBP 1,195,000 for the same period a year ago. Profit and total comprehensive income for the period attributable to equity holders of the parent company was GBP 1,898,000 or 2.30 pence per diluted share compared to loss and total comprehensive loss for the period attributable to equity holders of the parent company of GBP 1,063,000 or 1.41 pence per diluted share for the same period a year ago. Net cash generated from operating activities was GBP 3,372,000 compared to net cash used in operating activities of GBP 943,000 for the same period a year ago. Purchase of property, plant and equipment was GBP 7,000 compared to GBP 3,000 for the same period a year ago. Purchase of intangible assets was GBP 3,000 compared to GBP 16,000 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SNG:LN 32.50 GBp +0.50

SNG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SNG.
View Industry Companies
 

Industry Analysis

SNG

Industry Average

Valuation SNG Industry Range
Price/Earnings 22.8x
Price/Sales 6.5x
Price/Book 3.0x
Price/Cash Flow 23.6x
TEV/Sales 6.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNAIRGEN PLC, please visit www.synairgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.